Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to do a HIMS stock analysis & discuss the risks and upside potential of HIMS stock

1 extracted signal · 0 resolved · 0 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
16 Apr 2026, 21:16 UTC
Recorded by Tahlil Plus
18 May 2026, 20:24 UTC
Video preview for Friends! In this video, I'm going to do a HIMS stock analysis & discuss the risks and upside potential of HIMS stock
Source overview

AI-generated source summary

The stock HIMS has shown a significant bullish trend over the past five days, driven by positive news regarding the acquisition of a US-based peptide facility and the success of its weight-loss products. The company's growth in subscriber numbers and expansion into international markets, coupled with a decreasing short interest, indicate a strong positive outlook. The stock is currently trading at a P/S ratio of 1.8x, which is considered cheap for a growth stock, suggesting potential for further upside. The company's guidance for 2030 revenue and adjusted EBITDA further supports a bullish thesis, with the stock showing a significant growth potential over the next 4-5 years.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
1
Cancelled, invalid or excluded
Resolved success
—
0 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  6. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.9
Tracked signals
355
Historical success
34.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail